ReposiTrak Inc Dossier - Source-backed chat

ReposiTrak Inc

TRAKNYSE

SectorInformation Technology

IndustryApplication Software

Beta (adjusted)0.90

Intrinsic Value $11.23median of 6 methods · middle span $9-$17based on filings through 31 Mar 2026

Market Price $8.35Price as of 1 Oct 2026

UndervaluedIntrinsic value is 35% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $152M

Enterprise Value $125.7M

Shares Outstanding 19M diluted

Moat Rating Wide

Next Earnings Date12 Nov 2026

Last ex-dividend30 Jun 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ReposiTrak, Inc. (NYSE: TRAK) is uniquely positioned as a market leader in food traceability and regulatory compliance software. The company's proprietary Touchless Traceability platform is experiencing strong tailwinds driven by the FDA's Food Safety Modernization Act (FSMA) Section 204 mandates. With over 98% recurring SaaS revenue, high gross margins exceeding 85%, zero bank debt, and a robust cash position representing a significant portion of its market capitalization, ReposiTrak offers a highly defensive business model with substantial growth optionality as food supply chain participants accelerate compliance onboarding.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$16.00

Mean target$16.00

High · most bullish analyst$16.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$8.0010%

Further regulatory delays or extensions of the FSMA 204 compliance timeline by the FDA lead to a prolonged onboarding cycle, keeping revenue growth flat. Increased competition from generic supply chain software providers pressures pricing power, leading to margin compression.

Base CaseCentral scenario

$13.0460%

Steady onboarding of food suppliers and retailers continues, maintaining high single-digit revenue growth. The company successfully completes its preferred share redemptions by December 2026, simplifying its capital structure and increasing net income attributable to common shareholders. Operating margins remain stable around 32-35%.

Bull CaseUpside scenario

$16.0030%

Accelerated onboarding of grocery retailers and wholesalers ahead of the FSMA 204 compliance deadlines drives double-digit subscription revenue growth. Operating leverage from the highly scalable SaaS platform expands operating margins beyond 40%, while the SPAR Group partnership delivers visible financial impact within 6 to 9 months.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Highly predictable business model with recurring SaaS revenue exceeding 98% of total sales.
Strong balance sheet with $26.4 million in cash, zero bank debt, and positive operating cash flow.
Regulatory tailwinds from FDA FSMA 204 compliance mandates driving long-term customer adoption.
Exceptional profitability profile with gross margins of approximately 85% and operating margins over 30%.

Key Investment Risks

Regulatory risk if the FDA further delays or alters the enforcement of FSMA 204 compliance timelines.
Customer concentration and dependency on major grocery wholesalers and retail networks for supplier onboarding.
Relatively low stock liquidity which may increase price volatility.

Thesis Invalidation Triggers

A formal announcement by the FDA indefinitely postponing or canceling the FSMA 204 traceability requirements.
A significant decline in recurring revenue or a spike in customer churn rates.
Failure to execute the onboarding queue, resulting in prolonged flat year-over-year revenue growth.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.